

Hydrolysis of Human Plasma High Density Lipoprotein₂-
Phospholipids and Triglycerides by Hepatic Lipase

Kohji Shirai, Roger L. Barnhart and Richard L. Jackson
Division of Lipoprotein Research, Departments of Pharmacology
and Cell Biophysics, Biological Chemistry and Medicine
University of Cincinnati College of Medicine
Cincinnati, OH 45267

Received February 23, 1981

SUMMARY

To determine the physiological role of hepatic lipase in lipoprotein metabolism, human plasma very low (VLDL), low (LDL) or high (HDL₂ and HDL₃) density lipoproteins were labeled with [¹⁴C] triolein or [¹⁴C] dipalmitoyl phosphatidylcholine and the rates of lipid hydrolysis were determined using human heparin-releasable hepatic lipase. Compared to LDL and HDL₃, HDL₂ phospholipids were the preferred substrate for hepatic lipase; 17% of HDL₂ phospholipids were hydrolyzed. [¹⁴C] Triolein-labeled HDL₂ were also hydrolyzed by hepatic lipase. However, purified bovine milk lipoprotein lipase had negligible activity on HDL₂-triglycerides. After incubation of HDL₂ with hepatic lipase, there was a decrease in the size of the particle as demonstrated by gel filtration and an increase in the density as shown by zonal ultracentrifugation. These results suggest that hepatic lipase may play a role in the interconversion of HDL subfractions.

INTRODUCTION

Intravenous administration of heparin into man releases at least two distinct lipase activities. One enzyme, lipoprotein lipase, is located at the endothelial surface of extrahepatic cells, requires apolipoprotein C-II for maximal activity, is inhibited by 1 M NaCl and hydrolyzes chylomicron and VLDL triglycerides (Ref. 1, for review). A second enzyme, termed hepatic lipase, does not require a protein cofactor, is not inhibited by NaCl and is located on surface of the liver endothelial cells (2). The metabolic function of hepatic lipase in lipoprotein metabolism is not well understood. The enzyme may take part in the catabolism of remnantsof triglyceride-rich lipoproteins (1,3,4). In addition, recent studies suggest that hepatic lipase may play a role in HDL metabolism in the rat (5,6). Jansen et al. (5) and Kuusi et al. (6) showed that when the activity of hepatic lipase was blocked by the intravenous injection of antiserum prepared against hepatic lipase, there was an accumulation of HDL₂ cholesterol and phospholipid in the perfusate.

Abbreviations: VLDL (very low), LDL (low) and HDL (high) density lipoproteins.

0006-291X/81/100591-09\$01.00/0

Copyright © 1981 by Academic Press, Inc.
All rights of reproduction in any form reserved.

The role of hepatic lipase in the metabolism of human lipoproteins is based on clinical correlations. Kuusi et al. (7) have shown that there is an inverse correlation between the activity of hepatic lipase of post-heparin plasma and HDL₂ cholesterol, phospholipid and protein concentrations; no correlation existed between HDL₃ lipids and hepatic lipase. The purpose of the present study was to test these clinical correlations in an *in vitro* system consisting of purified human hepatic lipase and lipoproteins. We conclude from these studies that HDL₂ are the preferred substrate for hepatic lipase.

MATERIALS AND METHODS

Purification of hepatic lipase and lipoprotein lipase. Hepatic lipase was purified from human post-heparin plasma by affinity chromatography on heparin-Sepharose as described by Iverius and Ostlund-Lindqvist (8). The fractions corresponding to hepatic lipase were dialyzed against ammonium sulfate (60%). The resultant precipitate was dissolved in 50% glycerol, 10 mM Tris-HCl, pH 7.4, dialyzed against the same buffer, and stored at -70 °C. Hepatic lipase activity was determined using [¹⁴C] triolein as substrate. The standard assay mixture contained 0.378 μmol triolein (Sigma), 0.067 μCi tri[¹⁴C] oleoyl glycerol (New England Nuclear, specific activity = 50 mCi/mmol), 2% fatty-acid free bovine serum albumin (Fraction V, Sigma), 0.02% Triton X-100, 0.1 M Tris-HCl, pH 8.0 and enzyme protein in a final volume of 0.25 ml. Released [¹⁴C] oleic acid was extracted by the method of Belfrage and Vaughan (9). The specific activity of the purified enzyme was 750 mU/mg protein; 1 mU equals the release of 1 nmol free fatty acid/min in the standard assay.

Lipoprotein lipase was purified from bovine milk by affinity chromatography on heparin-Sepharose as described previously (10). The purified enzyme had a specific activity of 350 μmol free fatty acid released/min/mg protein using [¹⁴C] triolein as substrate, as described by Matsuoka et al. (10).

Preparation of lipoproteins. VLDL, $d < 1.006$ g/ml; LDL, $d = 1.020$ - 1.050 g/ml; and total HDL, $d = 1.063$ - 1.210 g/ml were isolated from plasma of normal fasting individuals by ultracentrifugation in salt solutions of KBr. Centrifugation was performed in a Beckman Model L5-65 with a type 50.2 Ti rotor operated at 4.8×10^4 rpm for 22 h at 8 °C. Lipoproteins were dialyzed against a standard buffer containing 10 mM Tris-HCl, pH 7.4, 1 mM EDTA and 0.01% NaN₃. Total HDL were further fractionated into HDL₂ and HDL₃ by zonal ultracentrifugation in a salt gradient of NaBr ($d = 1.00$ - 1.40 g/ml) as described by Patsch et al. (11). Zonal ultracentrifugation was performed at 41,000 rpm and 10 °C for 22 h in a Beckman Ti-14 zonal rotor using a L5-65 ultracentrifuge.

Preparation of [¹⁴C] triolein-labeled VLDL and HDL₂. VLDL were labeled with [¹⁴C] triolein as described by Fielding (12). Tri[1-¹⁴C] oleoyl glycerol (10 μCi, specific activity 50 mCi/mmol, New England Nuclear) was dissolved in 1 ml of dimethylsulfoxide, diluted to 4 ml with standard buffer and then VLDL (40 mg triglyceride in 10 ml of standard buffer) were added. After incubation for 3 h at 37 °C, the reaction mixture was dialyzed against the standard buffer and the VLDL were reisolated by ultracentrifugation; [¹⁴C] triolein-labeled VLDL contained 1.5×10^5 cpm/mg triglyceride.

[¹⁴C] Triolein-labeled HDL₂ were prepared using [¹⁴C] triolein-labeled VLDL and a purified lipid transfer protein which was isolated from human lipoprotein-free plasma as reported previously (13). HDL₂ (2 mg triglyceride), [¹⁴C] triolein-labeled VLDL (20 mg triglyceride, 3×10^6 total cpm) and lipid transfer protein (1 mg) in a final volume of 15 ml of standard buffer were incubated for 3 h at 37 °C. The lipoprotein mixture was then fractionated on a column (1.8 x 80 cm) of Bio-Gel A5m equilibrated with standard buffer.

The fractions corresponding to HDL₂ were pooled and HDL₂ were reisolated by ultracentrifugation ($d = 1.063\text{--}1.210\text{ g/ml}$); [¹⁴C] triolein-labeled HDL₂ contained 6.6×10^4 cpm/mg triglyceride, corresponding to the exchange of 50% of HDL₂-triglyceride for VLDL-triglycerides.

Preparation of [¹⁴C] dipalmitoyl phosphatidylcholine-labeled LDL, HDL₂ and HDL₃. Dipalmitoyl phosphatidylcholine (20 mg) and 30 μCi of di[¹⁴C] palmitoyl phosphatidylcholine (specific activity 100 mCi/mmol, New England Nuclear) were dissolved in chloroform and evaporated in vacuo. Standard buffer was added to the lipid to give 6 mg phospholipid/ml and vesicles were prepared by sonication at 42 °C for 15 min using a Heat Systems Ultrasonics, Inc., Cell Disruptor (Model W-225R). [¹⁴C] Dipalmitoyl phosphatidylcholine was incorporated into LDL by using the radiolabeled phospholipid vesicles and bovine liver phospholipid exchange protein as described previously (14); [¹⁴C] dipalmitoyl phosphatidylcholine-labeled LDL contained 1.2×10^6 cpm/mg phospholipid. [¹⁴C] Phospholipid was incorporated into HDL₂ and HDL₃ using [¹⁴C] dipalmitoyl phosphatidylcholine-labeled LDL and bovine liver phospholipid exchange protein. The incubation mixtures contained either HDL₂ or HDL₃ (4 mg phospholipid), [¹⁴C] dipalmitoyl phosphatidylcholine-labeled LDL (1 mg phospholipid, 1.2×10^6 cpm total), 0.2% fatty acid-free bovine serum albumin, bovine liver phospholipid exchange protein (50 μg) in 5 ml of standard buffer. After 1 h at 37 °C, the incubation mixtures were applied to a column (1.6 x 80 cm) of Bio-Gel A5m equilibrated with standard buffer. The fractions corresponding to HDL₂ or HDL₃ were pooled and the lipoproteins were reisolated by ultracentrifugation between $d = 1.063\text{--}1.210\text{ g/ml}$. [¹⁴C] Dipalmitoyl phosphatidylcholine-labeled HDL₂ and HDL₃ contained 1.3×10^5 and 1.5×10^5 cpm/mg phospholipid, respectively.

Other methods. [¹⁴C] Oleic acid which was released from [¹⁴C] triolein-labeled lipoproteins was extracted by the method of Belfrage and Vaughan (9). The release of [¹⁴C] lysopalmitoyl phosphatidylcholine from radiolabeled lipoproteins was determined as follows: To the incubation mixture (0.25 ml) was added 0.25 ml H₂O, 1.25 ml MeOH and 0.625 ml CHCl₃. After shaking at 0 °C for 30 min, 0.625 ml CHCl₃ and 0.75 ml of H₂O were added; the samples were shaken at 0 °C for 30 min. After centrifugation, the CHCl₃ phase was removed and evaporated to dryness with nitrogen. The lipids were redissolved in CHCl₃ and applied to silica gel 60 (EM Reagents). The thin layer plates (0.25 mm) were developed in CHCl₃:MeOH:water (70:30:4); lipids were visualized with iodine vapor. The lipids were scraped from the plates and radioactivity was determined. Protein was determined according to Lowry et al. (15), using bovine serum albumin as standard. Phospholipid phosphorus was measured by the method of Bartlett (16).

RESULTS

Hydrolysis of HDL and LDL phospholipids. To determine the specificity of hepatic lipase for human lipoprotein phospholipids, HDL₂, HDL₃ and LDL were radiolabeled with [¹⁴C] dipalmitoyl phosphatidylcholine and the rate of hydrolysis by hepatic lipase was measured (Fig. 1). The hydrolysis of [¹⁴C] dipalmitoyl phosphatidylcholine in HDL₂ was 11% in 4 h, whereas the hydrolysis of radiolabeled phospholipid in HDL₃ and LDL was only 3.5% and 1.2%, respectively. To obtain the kinetic parameters K_m and V_{max} , rates of hydrolysis of phospholipid by hepatic lipase were measured at various concentrations of HDL₂ and HDL₃ phospholipids. As shown in Fig. 2-A, the rate of phospholipid hydrolysis increased as the concentration of lipoprotein increased up to 0.6 mM




FIGURE 1. Hydrolysis of [14 C] dipalmitoyl phosphatidylcholine (DPPC)-labeled HDL₂, HDL₃ and LDL by hepatic lipase. The reaction mixtures contained 100 μ g of phospholipid of [14 C] DPPC-labeled HDL₂ (●-●), HDL₃ (○-○) or LDL (○---○), 2% fatty acid-free bovine serum albumin, 0.1 M Tris-HCl, pH 8.0 and 30 mU of hepatic lipase in a final volume of 0.25 ml. At the indicated times, enzyme reactions were terminated with CHCl₃:MeOH and the released [14 C] lysopalmitoyl phosphatidylcholine was determined as described in Materials and Methods.

phospholipid; the Lineweaver-Burk double reciprocal plots of these data are shown in Fig. 2-B. The apparent value of Michaelis constants (K_m) for HDL₂ and HDL₃ phospholipids were 0.25 mM and 0.45 mM, respectively. The value of maximal reaction velocity (V_{max}) for HDL₂ phospholipids was 1.5 times greater than that for HDL₃ phospholipids.




FIGURE 2. (A) Effect of substrate concentration on hepatic lipase activity. Each reaction mixture contained the indicated amount of total phospholipid of [14 C] dipalmitoyl phosphatidylcholine-labeled HDL₂ (●-●) or HDL₃ (○-○), 2% fatty acid-free bovine serum albumin, 0.1 M Tris-HCl, pH 8.0 and 30 mU of hepatic lipase in a total volume of 0.25 ml. After incubation for 1 h at 37°C, enzyme reactions were terminated with CHCl₃:MeOH and [14 C] lysopalmitoyl phosphatidylcholine was determined as described in Materials and Methods. (B) Lineweaver-Burk double reciprocal plots of the kinetic data in (A). Reaction velocities [V] were determined at varying substrate concentrations [S] of HDL₂ (●-●) on HDL₃ (○-○).




FIGURE 3. (A) Hydrolysis of [^{14}C] triolein-labeled VLDL by hepatic lipase and lipoprotein lipase. Each reaction mixture contained [^{14}C] triolein-labeled VLDL (0.2 mM with respect to triglyceride), 2% fatty acid-free albumin, 0.1 M Tris-HCl, pH 8.0, 0.15 M NaCl and either 12 mU of hepatic lipase (●-●) or 25 mU of lipoprotein lipase (○-○). At the indicated times, enzyme reactions were terminated and released [^{14}C] oleic acids were extracted as described in Materials and Methods. (B) Hydrolysis of [^{14}C] triolein-labeled HDL₂ by hepatic lipase and lipoprotein lipase. The reaction mixtures were the same as described in (A), with the exception that the concentration of HDL₂-triglyceride was 0.1 mM; the amount of hepatic lipase and lipoprotein lipase was also the same.

Hydrolysis of VLDL and HDL₂ triglycerides. From the data described above, we conclude that hepatic lipase preferentially hydrolyzes HDL₂ phospholipids. In contrast to hepatic lipase, lipoprotein lipase has little if any activity on HDL phospholipids (17). It was also of interest to compare the two lipolytic enzymes for their ability to hydrolyze HDL₂ triglycerides. As shown in Fig. 3-B, hepatic lipase hydrolyzes not only HDL₂ phospholipids but also HDL₂ triglycerides. Furthermore, the hydrolysis of [^{14}C] triolein-labeled HDL₂ by hepatic lipase (12 mU) was 10-fold greater than with lipoprotein lipase (25 mU). In contrast to the results with HDL₂, the rate of hydrolysis of VLDL-triglycerides (using the same amount of hepatic and lipoprotein lipase as with HDL₂) was greater with lipoprotein lipase (Fig. 3-A).

Characterization of HDL₂ after incubation with hepatic lipase. [^{14}C] Dipalmitoyl phosphatidylcholine-labeled HDL₂ was incubated with hepatic lipase as described in Fig. 4. After incubation for 6 h, 17% of the radiolabeled phospholipid was hydrolyzed. Phospholipid mass determination showed that 15% of the total phospholipid was




FIGURE 4. Chromatography on Bio-Gel A5m of HDL₂ and HDL₂ incubated with hepatic lipase. [¹⁴C] Dipalmitoyl phosphatidylcholine-labeled HDL₂ (0.5 mg total phospholipid; 7.5×10^4 cpm total), 2% fatty acid-free bovine serum albumin, 0.1 M Tris-HCl, pH 8.0 and either minus (○---○) or plus (●---●) hepatic lipase (420 mU) in a total volume of 2.0 ml of standard buffer were incubated at 37 °C. The minus enzyme incubation mixture contained the same amount of glycerol as the plus enzyme mixture. After 6 h incubation, 0.3 ml of each reaction mixture was applied directly to a column (1.6 x 80 cm) of Bio Gel A5m equilibrated with 0.1 M Tris-HCl, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 0.01% NaN₃ and operated at room temperature. The column was eluted with the equilibration buffer at a flow rate of 10 ml/h.

FIGURE 5. Zonal ultracentrifugation of HDL₂ and HDL₂ incubated with hepatic lipase. The reaction mixtures were identical to those described in Fig. 4. After incubation for 6 h at 37 °C, total HDL (d 1.063–1.210 g/ml; 60 mg protein) were added to 2 ml of the reaction mixture and the sample was immediately subjected to zonal ultracentrifugation as described in Materials and Methods. (A) Minus hepatic lipase. (B) Plus hepatic lipase. For conciseness, only the HDL profile is shown; albumin was present at d > 1.25.

hydrolyzed. After incubation with hepatic lipase, HDL₂ were reisolated by ultracentrifugation at d = 1.210 g/ml. The phospholipid to protein ratio of control HDL₂ was 0.74. The corresponding ratio in HDL₂ incubated with hepatic lipase was 0.59, indicating a loss of phospholipid relative to protein. The alteration in HDL₂ composition was also reflected in the chromatographic and ultracentrifugation properties. Chromatography of HDL₂ which were incubated with hepatic lipase showed a decrease in the size of the particle as compared to the control HDL₂; the released [¹⁴C] palmitic acid and [¹⁴C] lysopalmitoyl phosphatidylcholine in the enzyme-treated HDL₂ were associated with the albumin fraction (Fig. 4). Zonal ultracentrifugation of HDL₂ is shown in Fig. 5.

In this experiment, radiolabeled HDL₂ were incubated with hepatic lipase and then total HDL (d 1.063-1.210 g/ml) were added; the mixture was subjected immediately to ultracentrifugation. HDL₂ which were incubated with albumin in the absence of the enzyme were isolated at a peak density of 1.136 g/ml, whereas the HDL₂ which were incubated with hepatic lipase had a peak density of 1.141 g/ml.

DISCUSSION

The results of the present study are of interest as they relate to two recent reports. Musliner et al. (18) showed that total human HDL triglycerides were hydrolyzed by human hepatic lipase in vitro. Van Tol et al. (19) have shown that rat heparin-releasable hepatic lipase hydrolyzed HDL₂ phospholipids; no attempt was made to determine the hydrolysis of HDL₂ triglycerides or to determine the lipoprotein specificity of the enzyme. The present report using human lipoproteins shows that hepatic lipase hydrolyzes not only HDL₂ phospholipids but also HDL₂ triglycerides. In addition, HDL₂ was the preferred substrate for the enzyme; HDL₃ phospholipids were hydrolyzed to a lesser extent. Lipoprotein lipase had negligible activity on HDL₂ triglycerides. At comparable enzyme concentrations, lipoprotein lipase hydrolyzed VLDL triglycerides more readily than hepatic lipase, whereas with HDL₂ triglycerides, hepatic lipase was more active. These in vitro data with human lipoproteins are consistent with clinical correlations observed in man (7,20). Elevated heparin-releasable hepatic lipase activity is associated with decreased concentrations of plasma HDL₂ phospholipids and cholesterol; low activity is associated with high concentrations of HDL₂ lipids (7). In contrast, lipoprotein lipase activity in postheparin plasma is directly correlated to HDL₂ lipids and indirectly to VLDL-triglycerides (20).

The finding that hepatic lipase hydrolyzes both HDL₂ phospholipids and triglycerides suggests that it may play a role in the interconversion of HDL subfractions. In this regard, Jansen and Hulsmann (21) have suggested that the depletion of phospholipids from HDL₂ by the action of liver lipase induces a transfer of unesterified cholesterol to tissues, the possible end result being the transformation of HDL₂ into HDL₃. HDL₃ could then serve as an acceptor for phospholipids and apoproteins produced during the hydrolysis of triglyceride-rich lipoproteins by lipoprotein lipase, as has been demon-

strated in vitro (22) and in vivo after heparin injection (23). The data in Fig. 5 suggest that hepatic lipase alone does not produce HDL₃ from HDL₂ in vitro. Other components within the plasma compartment may be required for this conversion. For example, specific lipid transfer proteins may be required for the removal of core lipid components within HDL₂ during catabolism by hepatic lipase. Experiments to test the possible role of lipid transfer proteins in the interconversion of HDL are currently in progress.

ACKNOWLEDGMENTS

This work was supported by U.S. Public Health Service grants HL-22619 and HL-23019 and by General Clinical Research Center grant RR-00068. We gratefully acknowledge the assistance of Mrs. Janet Simons and Mrs. Beatrice Menkhaus in preparing the manuscript for publication and of Ms. Gwen Kraft in preparing the figures. Special thanks go to Mr. Jeff Ellsworth for supplying the purified lipid transfer protein.

REFERENCES

1. Nilsson-Ehle, P., Garfinkel, A.S., and Schotz, M.C. (1980) *Ann. Rev. Biochem.* 49, 667-693.
2. Kuusi, T., Nikkilä, E.A., Virtanen, I., and Kinnunen, P.K.J. (1979) *Biochem. J.* 181, 245-246.
3. Chajek, T., Friedman, G., Stein, O., and Stein, Y. (1977) *Biochim. Biophys. Acta* 488, 270-279.
4. Bergman, E.N., Havel, R.J., Wolfe, B.M., and Bohmer, T. (1971) *J. Clin. Invest.* 50, 1831-1839.
5. Jansen, H., Van Tol, A., and Hülsmann, W.C. (1980) *Biochem. Biophys. Res. Commun.* 92, 53-59.
6. Kuusi, T., Kinnunen, P.K.J., and Nikkilä, E.A. (1979) *FEBS Lett.* 104, 384-387.
7. Kuusi, T., Saarinen, P., and Nikkilä, E.A. (1980) *Atherosclerosis* 36, 589-593.
8. Iverius, P.-H. and Östlund-Lindqvist, A.-M. (1976) *J. Biol. Chem.* 251, 7791-7795.
9. Belfrage, P., and Vaughan, M. (1969) *J. Lipid Res.* 10, 341-344.
10. Matsuoka, N., Shirai, K., and Jackson, R.L. (1980) *Biochim. Biophys. Acta* 620, 308-316.
11. Patsch, W., Schonfeld, G., Gotto, A.M., Jr., and Patsch, J.R. (1980) *J. Biol. Chem.* 255, 3178-3185.
12. Fielding, C.J. (1979) *Biochim. Biophys. Acta* 573, 255-265.
13. Ihm, J., Harmony, J.A.K., Ellsworth, J., and Jackson, R.L. (1980) *Biochem. Biophys. Res. Commun.* 93, 1114-1120.
14. Jackson, R.L., Cardin, A.D., Barnhart, R.L., and Johnson, J.D. (1980) *Biochim. Biophys. Acta* 619, 408-413.
15. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951) *J. Biol. Chem.* 193, 265-275.
16. Bartlett, G.R. (1959) *J. Biol. Chem.* 234, 466-468.
17. Eisenberg, S., Schurr, D., Goldman, H., and Olivecrona, T. (1978) *Biochim. Biophys. Acta* 531, 344-351.
18. Musliner, T.A., Herbert, P.N., and Kingston, M.J. (1979) *Biochim. Biophys. Acta* 575, 277-288.
19. Van Tol, A., Van Gent, T., and Jansen, H. (1980) *Biochem. Biophys. Res. Commun.* 94, 101-108.
20. Nikkilä, E.A. (1978) In, High Density Lipoproteins and Atherosclerosis (Gotto, A.M., Miller, N.E. and Oliver, M.F., eds.), Elsevier/North Holland, Amsterdam, 177.

21. Jansen, H., and Hülsmann, W.C. (1980) Trends Biochem. Sci. 5, 265-268.
22. Patsch, J.R., Gotto, A.M., Jr., Olivecrona, T., and Eisenberg, S. (1978) Proc. Natl. Acad. Sci. USA 75, 4519-4523.
23. Forte, T.M., Krauss, R.M., Lindgren, F.T., and Nichols, A.V. (1979) Proc. Natl. Acad. Sci. USA 76, 5934-5938.